Implementation of dupilumab in routine care of atopic eczema. Results from the German national registry TREATgermany

Abraham S, Haufe E, Harder I, Heratizadeh A, Kleinheinz A, Wollenberg A, Weisshaar E, Augustin M, Wiemers F, Zink A, Biedermann T, Von Kiedrowski R, Hilgers M, Worm M, Pawlak M, Sticherling M, Fell I, Handrick C, Schaekel K, Staubach P, Asmussen A, Schwarz B, Bell M, Neubert K, Effendy I, Bieber T, Homey B, Gerlach B, Tchitcherina E, Stahl M, Schwichtenberg U, Rossbacher J, Buck PM, Mempel M, Beissert S, Werfel T, Weidinger S, Schmitt J (2020)


Publication Type: Journal article

Publication year: 2020

Journal

DOI: 10.1111/bjd.18958

Abstract

The German atopic eczema (AE)-registry TREATgermany is a non-interventional multicenter patient cohort study for adult patients with currently moderate-to-severe disease activity or current/previous anti-inflammatory systemic treatment.1,2 Dupilumab has demonstrated to be an effective treatment for patients with moderate-to-severe AE in clinical trials.3-5 Real world evidence is now needed to evaluate its effectiveness and safety in routine care.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Abraham, S., Haufe, E., Harder, I., Heratizadeh, A., Kleinheinz, A., Wollenberg, A.,... Schmitt, J. (2020). Implementation of dupilumab in routine care of atopic eczema. Results from the German national registry TREATgermany. British Journal of Dermatology. https://doi.org/10.1111/bjd.18958

MLA:

Abraham, Susanne, et al. "Implementation of dupilumab in routine care of atopic eczema. Results from the German national registry TREATgermany." British Journal of Dermatology (2020).

BibTeX: Download